ArticlePediatric cardiology2008
Cribriform amplatzer device closure of fenestrated atrial septal defects: feasibility and technical aspects.
Article in Pediatric cardiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- When 2D is not enough: 3D transesophageal echocardiography revealing a multifenestrated atrial septal defect.Journal of cardiovascular imaging · 2026Article
- Initial Experience With an Amplatzer Cribriform Occluder in Patients With Atrial Septal Defects in Pakistan.Cureus · 2024Article
- Can Artificial Intelligence Revolutionize the Diagnosis and Management of the Atrial Septal Defect in Children?Diagnostics (Basel, Switzerland) · 2024Review
- Three-Dimensional Cardiac Imaging: A Necessity to the Diagnosis and Treatment of Swiss-Cheese Atrial Septal Defect.Cureus · 2023Article
- Review
- Practical Therapeutic Management of Percutaneous Atrial Septal Defect Closure.Internal medicine (Tokyo, Japan) · 2022Article
- Individualized Experience With Percutaneous Transcatheter Closure of Multiple Atrial Septal Defects: A Single-Center Study.Frontiers in cardiovascular medicine · 2021Article
- Outcomes of Device Closure of Atrial Septal Defects.Children (Basel, Switzerland) · 2020Review
- Atrial septal defect closure: indications and contra-indications.Journal of thoracic disease · 2018Review
- Recent advances in managing septal defects: atrial septal defects.F1000Research · 2017Review
- Fenestrated atrial septal defect percutaneously occluded by a single device: procedural and financial considerations.Cardiology and therapy · 2013Article
- Transcatheter closure of multiple secundum atrial septal defects using multiple occluder devices: A comparative experience between pediatric and adult patients.Annals of pediatric cardiologyArticle
- Use of cribriform amplatzer septal occluder in the pediatric population: Feasibility, safety, and technical considerations.Annals of pediatric cardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fenestrated atrial septal defects (F-ASDs) may pose a challenge to device closure; recently, a cribriform device with a minimal connecting intrawaist diameter and large, equal left- and right-sided discs has been designed to cover more than one adjacent defect. This study demonstrates the feasibility and technical aspects of closing F-ASDs using this new device. Sixteen patients between August 2003 and January 2006 were included in this study. The inclusion criterion was the presence of a F-ASD diagnosed by transesophageal echocardiography. One of the three available cribriform ASD device sizes (18, 25, or 35 mm) was implanted. Patients were followed for at least 1 year after the procedure. Thirteen patients had successful cribriform ASD device implantation (median age and weight, 12.5 years and 36 kg, respectively). Ten patients (62%) had an associated atrial septal aneurysm. The mean procedure time was 75.6 +/- 28.5 min and the mean fluoroscopy time 14.8 +/- 6.3 min. The RVEDD was significantly reduced, from a mean of 24.2 mm to 21.0 (p < 0.05). One patient developed atrial tachycardia requiring cardioversion during the procedure. There were no embolic events, heart block, or mortality. Complete closure was 10 of 13 (77 %) the next day and 12 of 13 (92%) at 6 and 12 months. We conclude that the cribriform Amplatzer device can be successfully and safely used in patients with F-ASDs. Complete closure may take up to 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.